UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 24, 2015
Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
| | | | |
| Delaware | | 000-30929 | | 13-4087132 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)
(212) 531-5965
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | ¨ | Written communications pursuant to Rule 425 under the Securities Act. |
| | ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
| | ¨ | Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. |
| | ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
On June 24, 2015, Keryx Biopharmaceuticals, Inc. (“Keryx” or the “Company”) issued a press release announcing that two national insurance providers have added Auryxia™, the first and only absorbable, iron-based phosphate binder for the treatment of elevated serum phosphorus levels in people with chronic kidney disease on dialysis,to their Medicare Part D formularies. Together, these new formularies will increase unrestricted access to Auryxia, across Medicare Part D and commercial insurance providers, to approximately 65 percent of people in the U.S. currently taking phosphate binders.
A copy of the press release is being furnished as Exhibit 99.1 to this report.
| Item 9.01. | Financial Statements and Exhibits. |
The following exhibit is furnished as part of this report:
| | |
Exhibit
Number | | Description |
| |
| 99.1 | | Press Release dated June 24, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | Keryx Biopharmaceuticals, Inc. |
| | | | (Registrant) |
| | | |
| Date: June 24, 2015 | | | | | | |
| | | |
| | | | By: | | /s/ James F. Oliviero |
| | | | | | James F. Oliviero |
| | | | | | Chief Financial Officer |
INDEX TO EXHIBITS
| | |
Exhibit
Number | | Description |
| |
| 99.1 | | Press Release dated June 24, 2015. |
